Najjar YG, et al. - In this work, researchers sought to present an updated analysis of the pivotal E1684, E1690, E1694, and E2696 trials of adjuvant high-dose interferon-α (HDI) that enrolled nearly 2000 patients, and demonstrated HDI as the standard of care in adjuvant therapy for patients with resected high-risk melanoma. In these data, a median follow-up of 17.9 years for the E1684 trial, 12.2 years for the E1690 trial, 16.0 years for the E1694 trial, and 16.5 years for the E2696 trial were represented. In the E1684 and E1694 trials, adjuvant HDI led to improved recurrence-free survival (RFS) in these patients, and in the E1694 trial, it led to improved melanoma-specific survival (MSS). For the benefit of HDI with respect to RFS and MSS, these findings seem to represent the most mature level of evidence. Data were available for only HDI (the approved adjuvant treatment) in patients with resected stage IIB/IIC melanoma, and it remains a reasonable treatment option in this population.